Anti-angiogenic therapy
View Patent ↗The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
1. A method for reducing side effects of a VEGF-inhibiting anti-angiogenic agent in a therapy for inhibiting undesired angiogenesis, said method comprising decreasing, in said therapy, the effective amount of said VEGF-inhibiting anti-angiogenic agent and adding a PlGF-neutralizing agent, such combined therapy reducing said side effects, said PlGF-neutralizing agent being an antibody comprising a variable heavy chain sequence of which the sequence of the CDR1, CDR2, and CDR3 region corresponds to the sequence of SEQ ID NO: 17, 18, and 19, respectively, and comprising a variable light chain sequence of which the sequence of the CDR1, CDR2, and CDR3 region corresponds to the sequence of SEQ ID NO: 20, 21, and 22, respectively.
2. A method for inhibiting undesired angiogenesis, said method comprising adding a PlGF-neutralizing agent to a therapy for inhibiting undesired angiogenesis with a VEGF-inhibiting anti-angiogenic agent, wherein the effective amount of the VEGF-inhibiting anti-angiogenic agent in said therapy is decreased compared to its effective amount in a therapy for inhibiting undesired angiogenesis with the VEGF-inhibiting anti-angiogenic agent, such combined therapy inhibiting undesired angiogenesis, said PlGF-neutralizing agent being an antibody comprising a variable heavy chain sequence of which the sequence of the CDR1, CDR2, and CDR3 region corresponds to the sequence of SEQ ID NO: 17, 18, and 19, respectively, and comprising a variable light chain sequence of which the sequence of the CDR1, CDR2, and CDR3 region corresponds to the sequence of SEQ ID NO: 20, 21, and 22, respectively.
3. The method of claim 1 wherein said PlGF-neutralizing agent and said VEGF-inhibiting anti-angiogenic agent are combined via simultaneous or sequential administration.
4. The method of claim 1 wherein said undesired angiogenesis is a pathological condition selected from the group consisting of cancer, inflammation, adhesion formation, diseases of the eye, pulmonary hypertension and vascular leakage.
5. The method of claim 2 wherein said PlGF-neutralizing agent and said VEGF-inhibiting anti-angiogenic agent are combined via simultaneous or sequential administration.
6. The method of claim 2 wherein said undesired angiogenesis is a pathological condition selected from the group consisting of cancer, inflammation, adhesion formation, diseases of the eye, pulmonary hypertension and vascular leakage.